Triptorelin Market To Surpass US$ 670 Million By 2026 At a CAGR of 5 2% | Extended Application of Tr pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Drug major Sun Pharmaceutical Industries on Wednesday said it has entered into a licensing agreement with Ferring Pharmaceuticals to commercialise innovative obstetric drug Caritec in India. One of the company s wholly-owned subsidiaries has entered into a license agreement with Ferring Pharmaceuticals Pvt Ltd a subsidiary of Switzerland-based Ferring Pharmaceuticals to commercialise a room temperature stable formulation of the obstetric drug Caritec in India, Sun Pharma said in a regulatory filing. The drug is indicated for the prevention of excessive bleeding in women after vaginal or caesarean childbirth, it added. As per the agreement, Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name Caritec.
As per the agreement, Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name Caritec. Ferring has developed the drug and received approval from the Drugs Controller General of India (DCGI) for introducing the medicine in India, Sun Pharma said.